COSCIENS Biopharma Inc. Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset
COSCIENS Biopharma Inc. (CSCIF) reported Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset of -$1.92 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Income Statement › Other Income
ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset · last filed 2026-03-25
- COSCIENS Biopharma Inc. actuarial gains losses arising from changes in financial assumptions net defined benefit liability asset for the quarter ending 2025-12-31 was -$677.00K, a 371.89% decline year-over-year.
- COSCIENS Biopharma Inc. actuarial gains losses arising from changes in financial assumptions net defined benefit liability asset for the quarter ending 2025-09-30 was $1.00K.
- COSCIENS Biopharma Inc. actuarial gains losses arising from changes in financial assumptions net defined benefit liability asset for the quarter ending 2025-06-30 was -$129.00K.
- COSCIENS Biopharma Inc. actuarial gains losses arising from changes in financial assumptions net defined benefit liability asset for the quarter ending 2025-03-31 was -$1.11M.
| Period end | Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset 3 month | Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset 6 month | Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset 9 month | Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset 12 month | Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$677.00K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-25 | -$676.00K derived: sum of 2 quarters · filed 2026-03-25 | -$805.00K derived: sum of 3 quarters · filed 2026-03-25 | -$1.92M 20-F · filed 2026-03-25 | |
| 2025-09-30 | $1.00K derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | -$128.00K derived: sum of 2 quarters · filed 2025-11-12 | -$1.24M 6-K · filed 2025-11-12 | -$990.00K derived: sum of 4 quarters · filed 2026-03-25 | |
| 2025-06-30 | -$129.00K derived: 6-K 6 month − 6-K 3 month · filed 2025-08-14 | -$1.24M 6-K · filed 2025-08-14 | -$991.00K derived: sum of 3 quarters · filed 2026-03-25 | ||
| 2025-03-31 | -$1.11M 6-K · filed 2025-05-13 | -$862.00K derived: sum of 2 quarters · filed 2026-03-25 | |||
| 2024-12-31 | $249.00K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-25 | $1.19M 20-F · filed 2026-03-25 | |||
| 2024-09-30 | $937.00K 6-K · filed 2024-11-12 | ||||
| 2024-03-31 | -$319.00K 6-K · filed 2024-05-16 | $2.14M derived: sum of 2 quarters · filed 2024-07-17 | $751.00K derived: sum of 3 quarters · filed 2024-07-17 | $746.00K derived: sum of 4 quarters · filed 2024-07-17 | |
| 2023-12-31 | $2.46M derived: 20-F/A 12 month − 6-K 9 month · filed 2024-07-17 | $1.07M derived: sum of 2 quarters · filed 2024-07-17 | $1.06M derived: sum of 3 quarters · filed 2024-07-17 | $1.21M 20-F/A · filed 2024-07-17 | |
| 2023-09-30 | -$1.39M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-09 | -$1.40M derived: sum of 2 quarters · filed 2023-11-09 | -$1.25M 6-K · filed 2023-11-09 | -$15.69M derived: sum of 4 quarters · filed 2024-07-17 | |
| 2023-06-30 | -$5.00K derived: 6-K 6 month − 6-K 3 month · filed 2023-08-09 | $143.00K 6-K · filed 2023-08-09 | -$14.30M derived: sum of 3 quarters · filed 2024-07-17 | -$15.57M derived: sum of 4 quarters · filed 2024-07-17 | |
| 2023-03-31 | $148.00K 6-K · filed 2023-05-09 | -$14.29M derived: sum of 2 quarters · filed 2024-07-17 | -$15.57M derived: sum of 3 quarters · filed 2024-07-17 | -$8.96M derived: sum of 4 quarters · filed 2024-07-17 | |
| 2022-12-31 | -$14.44M derived: 20-F/A 12 month − 6-K 9 month · filed 2024-07-17 | -$15.72M derived: sum of 2 quarters · filed 2024-07-17 | -$9.11M derived: sum of 3 quarters · filed 2024-07-17 | -$5.92M 20-F/A · filed 2024-07-17 | |
| 2022-09-30 | -$1.27M derived: 6-K 9 month − 6-K/A 6 month · filed 2022-11-03 | $5.33M derived: sum of 2 quarters · filed 2022-11-03 | $8.53M 6-K · filed 2022-11-03 | ||
| 2022-06-30 | $6.61M derived: 6-K/A 6 month − 6-K 3 month · filed 2022-08-04 | $9.80M 6-K/A · filed 2022-08-04 | |||
| 2022-03-31 | $3.19M 6-K · filed 2022-05-11 | ||||
| 2021-12-31 | -$1.13M 20-F/A · filed 2024-02-15 | $1.13M 6-K · filed 2022-05-11 | |||
| 2019-09-30 | -$536.00K derived: 6-K 9 month − 6-K 6 month · filed 2019-11-07 | -$2.03M 6-K · filed 2019-11-07 | |||
| 2019-06-30 | -$1.49M 6-K · filed 2019-08-13 | ||||
| 2018-12-31 | $174.00K 6-K · filed 2019-11-07 |